APA (7th ed.) Citation

L, A., AG, L., I, L., D, M., A, I., DL, D., & F, L. (2026). Metabolic Dysfunction-Associated Steatotic Liver Disease and Incretin Receptor Agonists: A Metabolic Approach to Halting Liver Disease Progression. Medicina (Kaunas, Lithuania), 62(5), . https://doi.org/10.3390/medicina62050986

Chicago Style (17th ed.) Citation

L, Abenavoli, Loricchio AG, Lopez I, Morano D, Ismaiel A, Dumitrascu DL, and Luzza F. "Metabolic Dysfunction-Associated Steatotic Liver Disease and Incretin Receptor Agonists: A Metabolic Approach to Halting Liver Disease Progression." Medicina (Kaunas, Lithuania) 62, no. 5 (2026). https://doi.org/10.3390/medicina62050986.

MLA (9th ed.) Citation

L, Abenavoli, et al. "Metabolic Dysfunction-Associated Steatotic Liver Disease and Incretin Receptor Agonists: A Metabolic Approach to Halting Liver Disease Progression." Medicina (Kaunas, Lithuania), vol. 62, no. 5, 2026, https://doi.org/10.3390/medicina62050986.